Quality of life, symptom profile and clinical efficacy of second-line treatment with dasatinib in patients with imatinib-resistant or -intolerant chronic myeloid leukemia: results of 2-year follow-up

The article is focused on the results of the multicenter observational study “Quality of life and symptom profile in patients with chronic myeloid leukemia in chronic phase in long-term follow-up of second-line treatment” (2012–2015). Thirty imatinib-resistant or-intolerant patients with chronic myeloid leukemia in chronic phase were observed in the real-world clinical setting during 24 months after start of second-line treatment with dasatinib. Mean age – 48 years old (SD = 13.1); males / females – 14 / 16; one third of patients were with comorbidity, Charlson Index – 0–5 scores. All the patients received dasatinib in the dosage of 100 mg daily. Study time points – 12, 18 and 24 months after second-line treatment start. Treatment outcomes were analyzed in terms of clinical efficacy and safety as well as in terms of patient-reported outcomes, including quality of life and symptom profile assessment. For quality of life and symptom assessment the SF-36 and CSP-CML questionnaires were used, respectively. Statisticallly significant changes in quality of life and symptom severity were analyzed by generalized estimated equation (GEE). Complete hematological response was observed in 96.3 % patients, complete cytogenetic response – in 66.6 % patients, complete or major molecular response – in 60 % patients. The acceptable tolerability of dasatinib treatment was shown during long-term follow-up: hematological and non-hematological serious adverse events were rare and didn’t lead to treatment discontinuation. Significant improvement of physical functioning, role physical functioning, role emotional functioning, vitality and mental health as compared to base-line parameters was observed (p < 0.05). The severity of a number pronounced symptoms decreased and the proportion of patients with severe symptoms reduced (p = 0.01) after 24 months of second-line treatment start. Quality of life treatment response in terms of stabilization or improvement was registered in 83 % of patients. The data of this real-world study in CML patients are in line with the results of clinical studies in terms of dasatinib treatment efficacy and safety. In addition, they demonstrate the value of patient-reported outcomes to evaluate benefits and risks of long-term dasatinib treatment from patient perspective.

quality of life, symptom profile, chronic myeloid leukemia, dasatinib, treatment efficacy, safety, long-term follow-up

1. Baccarani M., Pileri S., Steegmann J.-L. et al. Chronik myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(7):72–7.

2. Baccarani M., Deininger M.W., Rosti G. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122(6):872–84.

3. Голенков А.К., Высоцкая Л.Л., Трифонова Е.В. и др. Эффективность лечения больных хроническим миелолейкозом иматинибом в широкой клинической практике. Онкогематология 2012;3:17–21. [Golenkov A.K., Vysotskaya L.L., Trifonova E.V. et al. Treatment efficacy of chronic myeloid leukemia with imatinib in clinical pravtice. Onkogematologiya = Oncohematology 2012;3:17–21. (In Russ.)].

4. Практические аспекты терапии хронического миелолейкоза в хронической фазе (по материалам выступлений на Конгрессе гематологов). Москва, 3 июля 2012 г. Онкогематология 2012;3:8–16. [Practical aspects of chronic myeloid leukemia treatment in chronic phase (According to the presentations of the Congress of Hematology. Moscow, July 3, 2012. Onkogematologiya = Oncohematology 2012;3:8–16. (In Russ.)].

5. Bubnoff N., Duyster J. Chronic myelogenous leukemia treatment and monitoring. Dtsch Arztebl Int 2010;107(7): 114–21.

6. Quintas-Cardama A., Cortes J.E., O’Brien S. et al. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 2009:2912–21.

7. Hochhaus A., Baccarani M., Deininger M. et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22(6):1–7.

8. Ottmann O., Dombret H., Martinelli G. et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007;110:2309–15.

9. Shah N.P., Cortes J.E., Schiffer C.A. et al. Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. J Clin Oncol 2011;29:1634–42.

10. Ломаиа Е.Г., Романова Е.Г., Сбитякова Е.И., Зарицкий А.Ю. Эффективность и безопасность ингибиторов тирозинкиназ 2-го поколения (дазатиниб, нилотиниб) в терапии хронической фазы хронического миелолейкоза. Онкогематология 2013;2:22–33. [Lomaia E.G., Romanova E.G., Sbityakova E.I., Zaritskiy A.Yu. Efficacy and safety of tyrosinkinase inhibitors (Dasatinib, Nilotinib) in the treatment of chronic phase chronic myeloid leukemia. Onkogematologiya = Oncohematology 2013;2:22–33. (In Russ.)].

11. Волкова М.А. Новые возможности в терапии хронического миелолейкоза: дазатиниб. Клиническая онкогематология 2008;1(3):218–25. [Volkova M.A. New possibilities in the treatment of chronic myeloid leukemia: Dasatinib. Klinicheskaya onkogematologiya = Clinical Oncohematology 2008;1(3):218–25. (In Russ.)].

12. Shah N., Kim D., Kantarjian H. et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95(2):232–40.

13. Wong S.F. New dosing schedules of dasatinib for CML and adverse event management. J Hematol Oncol 2009;2:10.

14. Krauth M., Herndlhofer S., Schmook M. et al. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica 2011;96(1):163–6.

15. Guidelines. Patient-reported outcomes in hematology. The EHA SWG “Quality of life and symptoms”. Forum Service Editore. Genoa, Forum Service Editore, 2012. 206 p.

16. Eficace F., Cocks K., Breccia M. et al. Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol 2012;81:123–35.

17. Efficace F., Rosti G., Aaronson N. et al. Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica 2014;99(4):788–93.

18. Efficacе F., Cardoni A., Cottone F. et al. Tyrosinekinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: A systematic review. Leuk Res 2013;37(2): 206–13.

19. Baccarani M., Efficace F., Rosti G. Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden. Haematologica 2014;99(2):205–8.

20. Челышева Е.Ю., Галактионова А.В., Туркина А.Г. Проблема приверженности терапии хронического миелолейкоза: понять пациента и найти решения. Клиническая онкогематология 2013;6(2):157–65. [Chelysheva E.Yu., Galaktionova A.V., Turkina A.G. The commitment problem in treatment of chronic myeloid leukemia: to understand the patient and to find solutions. Klinicheskaya onkogematologiya = Clinical Oncohematology 2013;6(2):157–65. (In Russ.)].

21. US Food and Drug Administration. Guidance for industry: patient-reported outcome measures; use in medical product development to support labeling claims Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071975.pdf. Accessed September 8, 2009.

22. Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине. 3-е изд. Под ред. акад. РАМН Ю.Л. Шевченко. М., 2012. [Novik A.A., Ionova T.I. Guidelines for quality of life assessment in Medicine. 3rd ed. Ed.: Acad. RAMS Yu.L. Shevchenko. Moscow, 2012. (In Russ.)].

23. Efficace F., Baccarani M., Breccia M. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011;118(17):4554–60.

24. Pinilla-Ibarz J., Cortes J., Mauro M.J. Side effects of targeted treatments: сlinicians’ perceptions, patients’ realities. Cancer 2011;117(4):688–97.

25. Williams L.A., Gonzales A.G., Ault P. et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 2013;122(5):641–7.

26. Ionova T., Nikitina T., Gritsenko T. et al. Quality of life and symptom profile in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Haematologica 2012;97(1):249.

27. Ионова Т.И., Федоренко Д.А., Никитина Т.П., Курбатова К.А. Качество жизни и профиль симптомов у больных хроническим миелолейкозом на фоне терапии второй линии дазатинибом при непереносимости и резистентности к иматинибу. Клиническая онкогематология 2013;6(2):166–75. [Ionova T.I., Fedorenko D.A., Nikitina T.P., Kurbatova K.A. Quality of life and symptoms profile in patients with chronic myeloid leukemia during second-line therapy withdasatinib after intolerance and resistance to imatinib. Klinicheskaya onkogematologiya = Clinical Oncohematology 2013;6(2):166–75. (In Russ.)].

28. Ionova T., Nikitina T., Gritsenko T. et al. Benefits/risks of dasatinib therapy in patients with imatinib-resistant or -intolerant chronic myeloid leukemia: physician’s and patient’s perspective. Haematologica 2013;(Suppl): B1381.

29. Ionova T.I., Nikitina T.P., Gritsenko T.A. et al. The value of dasatinib therapy in patients with imatinib-resistant or -intolerant chronic myeloid leukemia from physician’s and patient’s perspective: “real world” outcomes. Haematologica 2014;(Suppl):B1675.

30. Nikitina T.P., Fedorenko D.A., Kurbatova K.A. et al. Baseline Quality of Life in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to Imatinib and its Potential Prognostic Value. ELN Frontiers meeting. Abstr. 2014. P21.

31. Ionova T.I., Nikitina T.P., Fedorenko D.A. et al. Long-Term Outcomes of Dasatinib Therapy in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia from Physician’s and Patient’s Perspective. Blood 2014;124(21):А2644.

32. Kropf P., Barnes G., Tang B.. et al. Burden of tyrosine kinase inhibitor failure in patients with chronic myeloid leukemia. J Leuk 2015;3(1):170.

33. Hirji I., Gupta S., Goren A. et al. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes. From the patients’ perspective. Health and quality of life outcomes. 2013;11:167.

34. Абдулкадыров К.М., Абдуллаев А.О., Авдеева Л.Б. и др. Федеральные клинические рекомендации по диагностике и терапии хронического миелолейкоза. Вестник гематологии 2013;IX;(3):4–39. [Abdulkadyrov K.M., Abdullaev A.O., Avdeeva L.B. et al. Fedеral clinical guidelines for chronic myelogenous leukemia diagnosis and treatment. Vestnik gematologii = The Bulletin of Hematology 2013;IX;(3):4–39. (In Russ.)].

35. Carlson M.E., Pompei P., Ales K.L. et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.

36. Breccia M., Latagliata R., Stagno F. et al. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica 2011;96(10):1457–61.

37. Hays R.D., Sherbourne C.D., Mazel R.M. User’s Manual for Medical Outcomes Study (MOS) Core measures of health-related quality of life. RAND Corporation, MR-162-RC (available at www.rand.org).

38. Nikitina T.P., Fedorenko D.A., Kurbatova K.A. et al.Comprehensive symptom profile in patients with chronic myeloid leukemia: practicability and sensitivity of the new symptom assessment tool CSP Leuk-CML. Haematologica 2014;(Suppl):B1674.

39. Hochhaus A., Hagop M., Kantarjian H. et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109(6): 2303–9.

40. Rosti G., Castagnetti F., Gugliotta G. et al. Dasatinib and nilotinib in imatinib resistant

41. Philadelphia-positive chronic myelogenous leukemia: a “head-to-head” comparison. Leuk Lymphoma 2010;51:583–91.

42. Khoury J., Guilhot F., Hughes T. et al. Dasatinib treatment for Philadelphia chromosome-positive leukemias practical considerations. Cancer 2009;115:1381–4.

43. Quintas-Cardama A., Pires De Souza Santos F., Kantarjian H. et al. Dynamics and management of cytopenias associated withdasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure cancer. Cancer 2009;115(7):3935–43.

44. Jabbour E., Deininger M., Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2011;25:201–10.

45. Krauth M., Herndlhofer S., Schmook M. et al. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica 2011;96(1):163–6.

46. Quintas-Cardama A., Kantarjian H., O’Brien S. et al. Effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:136–40.

47. Masiello D., Gorospe G.S., Yang A.S. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol 2009;12(2):46.

48. Nagata Y., Ohashi K., Fukuda S. et al. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol 2010;91:799–807.